ABSTRACT: Activating mutations in FGFR3 cause the most common forms of human dwarfism: achondroplasia and thanatophoric dysplasia. In mouse models of achondroplasia, recent studies have implicated the ERK MAPK pathway, a pathway activated by FGFR3, in creating reduced bone growth. Our recent studies have indicated that increased Fgfr3 and ERK MAPK signaling in chondrocytes also causes premature synchondrosis closure in the cranial base and vertebrae, accounting for the sometimes fatal stenosis of the foramen magnum and spinal canal in achondroplasia. Conversely, whether the decrease-or inactivation-of ERK1 and ERK2 promotes bone growth and delays synchondrosis closure remains to be investigated. In this study, we inactivated ERK2 in the chondrocytes of ERK1-null mice using the Col2a1-Cre and Col2a1-CreER transgenes. We found that the genetic inactivation of ERK1 and ERK2 in chondrocytes enhances the growth of cartilaginous skeletal elements. We also found that the postnatal inactivation of ERK1 and ERK2 in chondrocytes delays synchondrosis closure and enlarges the spinal canal. These observations make ERK1 and ERK2 an attractive target for the treatment of achondroplasia and other FGFR3-related skeletal syndromes. The extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway consists of a series of kinases that play important roles in skeletal development. The ERK MAPK pathway is activated by various cytokines and growth factors, including family members of fibroblast growth factor (FGF). Activating mutations in FGF receptor 3 (FGFR3) cause the most common forms of human dwarfismachondroplasia, thanatophoric dysplasia, and hypochondroplasia. [1] [2] [3] [4] [5] [6] Mutations in the signaling molecules in the ERK MAPK pathway also cause a number of human skeletal disorders, including Noonan, Costello, and cardio-facio-cutaneous syndromes.
The extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway consists of a series of kinases that play important roles in skeletal development. The ERK MAPK pathway is activated by various cytokines and growth factors, including family members of fibroblast growth factor (FGF). Activating mutations in FGF receptor 3 (FGFR3) cause the most common forms of human dwarfismachondroplasia, thanatophoric dysplasia, and hypochondroplasia. [1] [2] [3] [4] [5] [6] Mutations in the signaling molecules in the ERK MAPK pathway also cause a number of human skeletal disorders, including Noonan, Costello, and cardio-facio-cutaneous syndromes. [7] [8] [9] The growth inhibitory roles of FGFR3 have been demonstrated in a number of mouse models and human skeletal syndromes. Mice that express a gain-of-function mutant of Fgfr3 show a dwarf phenotype similar to the human dwarfisms achondroplasia and thanatophoric dysplasia. [10] [11] [12] [13] In contrast, Fgfr3-null mice show skeletal overgrowth similar to that seen in human camptodactyly, tall stature, and hearing loss (CATSHL) syndrome, which is caused by a loss-of-function mutation in FGFR3. [14] [15] [16] Several lines of evidence have indicated that the ERK MAPK pathway is a critical downstream effector of Fgfr3. Growth plate chondrocytes expressing a human achondroplasia mutant of Fgfr3, for example, show increased levels of phosphorylated ERK1 and ERK2 and their upstream kinase MEK1. 17, 18 Furthermore, mice expressing a constitutively active mutant of MEK1 in chondrocytes show an achondroplasia-like dwarfism. 17 In addition, the overexpression of C-type natriuretic peptide (CNP) in chondrocytes causes skeletal overgrowth and rescues the dwarf phenotype in a mouse model of achondroplasia. 18 One of the actions of CNP is to inhibit the ERK MAPK pathway. 18, 19 Recent work in our laboratory has indicated that Fgfr3 and the ERK MAPK pathway also regulate synchondrosis closure. 20 A synchondrosis consists of two opposed growth plates with a common zone of resting chondrocytes. We found premature synchondrosis closure in the vertebrae and the cranial base of human samples of homozygous achondroplasia and thanatophoric dysplasia. We also observed premature synchondrosis closure in the cranial base and vertebrae of mice expressing the Fgfr3 G374R achondroplasia mutant and mice expressing a constitutively active MEK1 mutant in chondrocytes. These observations strongly suggest that premature synchondrosis closure accounts for the foramen magnum and spinal canal stenosis in achondroplasia. A common and serious complication of achondroplasia, 6, 21 foramen magnum and cervical spinal stenosis associated with compression of the brainstem and spinal cord can lead to sudden death during early childhood. 22 In addition, spinal canal stenosis can cause other neurologic complications such as radiculopathy, claudication, and paraparesis.
While increased ERK MAPK signaling has been implicated in reduced bone growth and premature synchondrosis closure, whether or not the specific inactivation of ERK1 and ERK2 in chondrocytes indeed accelerates bone growth and delays synchondrosis closure has remained to be investigated. In this study, we examined the effects of the genetic inactivation of ERK1 and ERK2 on bone growth and synchondrosis closure. We show here that the prenatal inactivation of ERK1 and ERK2 in chondrocytes results in increased growth of the long bones and vertebral bodies. We further show that the postnatal inactivation of ERK1 and ERK2 in chondrocytes delays synchondrosis closure in the vertebrae and enlarges the spinal canal. These observations clearly demonstrate the potential of targeting ERK1 and ERK2 for promoting bone growth and preventing premature synchondrosis closure in human dwarfisms such as achondroplasia.
MATERIALS AND METHODS

Mice
The institutional animal care and use committee approved all animal procedures. ERK1-null mice, mice with the floxed ERK2 allele, and Col2a1-Cre transgenic mice were described previously. [23] [24] [25] The generation of ERK1 À/À ; ERK2 flox/flox ; Col2a1-Cre (ERK1/2/Col2a1Cre) mice and their initial characterization were reported elsewhere. 26 For postnatal analysis, we used the Col2a1-CreER transgene to circumvent the perinatal lethality of ERK1/2/Col2a1Cre mice. 27 One milligram tamoxifen was injected subcutaneously into ERK1 ; ERK2 flox/flox mice at postnatal days 4 and 6 (P4, P6), and the animals were sacrificed at P8. Alternatively, 1 mg tamoxifen was injected subcutaneously at P7 and P9, and animals were sacrificed at P14.
Skeletal Preparations and Histological Examination
Skeletal preparations were stained with alcian blue and alizarin red following the standard protocol. Isolated bones were laid next to a ruler and photographed using a dissection microscope, a digital camera, and Leica Application software. Scion Image software (Scion Corporation, Frederick, MD) was used to measure bone lengths. For histological analysis, tissues were fixed in 10% formalin, demineralized in 0.5 M EDTA, and embedded in paraffin. Seven-micrometer thick sections were stained with hematoxylin, eosin, and alcian blue. Photographs were taken using Leica Application software, and the dimensions of the vertebral body and foramen were measured using Scion Image software. For consistency, only the 1st and 2nd lumbar vertebrae were used for the measurement. For immunostaining of CD31, sections were incubated with anti-CD31 (Abbiotec, San Diego, CA) antibody followed by horseradish-peroxidase/Fab polymer conjugate secondary antibody (Invitrogen, Carlsbad, CA, Picture Kit). Non-immune rabbit IgG was used as a control. Color was developed using 3,3 0 -diaminobenzidine (DAB). Osteoclasts were identified by TRAP staining. 26 TUNEL assay was performed using ApopTag Plus Fluorerscein In Situ Apoptosis Detection Kit (Millipore, Ballerica, MA).
Real-Time PCR
Epiphyseal cartilage of the tibia was dissected out from ERK1/ 2/Col2a1CreER mice and control mice at P8 and stored in RNAlater (Applied Biosystems, Carlsbad, CA). Tissues were homogenized using Powergen 500 (Fisher, Waltham, MA). RNA was extracted using RNeasy Mini Kit (Qiagen, Germantown, MD) and reverse transcribed by High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-time PCR was performed on the Applied Biosystems 7500 real-time PCR detection system using TaqMan probe sets (Erk2; Mm00442479_m1, Gapdh; 4352932E, Applied Biosystems). The comparative cycle threshold (Ct) method was used to compare gene expression levels.
Statistical Analysis of Data
Statistical analysis was performed using Analyse-it (Analyseit Software, Leeds, UK). A one-way ANOVA analysis with a post hoc pairwise Scheffe test was used to compare three genotypes at E18.5. The Mann-Whitney test was used to compare ERK1/2/Col2a1CreER and control mice at P8 and P14.
RESULTS
ERK1 and ERK2 Inactivation Enhances the Bone Growth of Proximal Long Bones
The length of each long bone was measured using skeletal preparations of E18.5 embryos (Fig. 1A) . While the radius, ulna, and tibia did not show statistically significant differences among genotypes, the humerus and femur were significantly longer in ERK1/2/Col2a1-Cre embryos in comparison to the embryos in which only one allele (ERK1
; Col2a1-Cre) of ERK1/2 were inactivated (Fig. 1B,C) . The width of each epiphysis was also measured at its widest point. ERK1/2/Col2a1Cre embryos had significantly wider epiphyses in the proximal and distal humerus and femur (Fig. 1D ). ERK1/2/Col2a1Cre embryos also showed wider epiphyses in the distal tibia (data not shown). These observations indicate that the inactivation of ERK1 and ERK2 in chondrocytes causes increased bone growth that is more pronounced in the proximal long bones.
ERK1 and ERK2 Inactivation Promotes the Growth of Cartilaginous Vertebrae
We also examined the dimensions of the vertebrae using histological sections of the lumbar vertebrae at E18.5 ( Fig. 2A) . Hematoxylin, eosin, and alcian blue staining showed a delay in ossification in ERK1/2/Col2a1Cre embryos compared with littermate control embryos (Fig. 2B) . While the vertebral body of control embryos was mostly ossified, the vertebral body of ERK1/2/ Col2a1Cre embryos remained entirely cartilaginous. ERK1/2/Col2a1Cre embryos also showed the persistent presence of hypertrophic chondrocytes both in the vertebral body and arch. The cross-sectional area of the vertebral body was significantly larger in ERK1/2/ Col2a1Cre embryos compared with control embryos, indicating increased growth (Fig. 2C) . The vertebral body of ERK1/2/Col2a1Cre embryos was larger both in the anterior-posterior and lateral directions (data not shown). In contrast to the measurements of the vertebral body, the cross-sectional area of the vertebral foramen was significantly smaller in ERK1/2/Col2a1Cre embryos compared with control ERK1 À/þ ; ERK2 flox/flox embryos (Fig. 2D) .
Postnatal ERK1 and ERK2 Inactivation Delays Synchondrosis Closure and Enlarges the Spinal Canal
To examine the roles of ERK1/2 in postnatal skeletal development, we inactivated ERK2 using the Col2a1-CreER transgene. Following tamoxifen injection at P4 and P6, ERK2 expression in the tibial epiphysis was inhibited about 60% in ERK1/2/Col2a1CreER mice at P8 (Fig. 3A) . Histological analysis indicated that the overall architecture of the epiphysis was not significantly affected (Fig. 3B) . However, ERK1/2/Col2a1CreER mice consistently showed a delay in vascular invasion in the developing secondary ossification centers at P8 (Fig. 3B) . We further examined VEGF expression in the epiphyses by real time PCR, but we did not observe differences between ERK1/2/Col2a1CreER and control mice (data not shown). There were no obvious differences in the dimensions of long bones at P8 and P14 (data not shown).
Histological analysis at P8 and P14 of the vertebrae of ERK1/2/Col2a1CreER mice showed a significant delay in the closure of neurocentral synchondroses, which connect the ossification centers in the vertebral body and arch (Fig. 4A,B) . The cross-sectional area of the neurocentral synchondrosis was significantly greater in ERK1/2/Col2a1CreER mice at P8, indicating a delay in cartilage resorption (p < 0.001) (Fig. 5A) . At P14, the neurocentral synchondroses were closed in five out of eight control ERK1 À/À ; ERK2 flox/flox mice, while the synchondroses were open in all seven ERK1/2/ Col2a1CreER mice. Furthermore, the cross-sectional area of the vertebral foramen was significantly greater in ERK1/2/Col2a1CreER mice both at P8 (p < 0.01) and P14 (p < 0.01), indicating that postnatal ERK1/2 inactivation in chondrocytes enlarges the spinal canal ( Fig. 5B and data not shown) .
Since ERK1/2/Col2a1-CreER mice showed a delay in cartilage resorption, we examined the number of osteoclasts by TRAP staining and examined chondrocyte apoptosis by TUNEL assay. We did not observe obvious differences in the number of osteoclasts and in chondrocyte apoptosis between genotypes (data not shown). We also examined vascular invasion by immunohistochemistry for endothelial marker CD31. We observed decreased staining for CD31 in endothelial cells surrounding the neurocentral synchondroses of ERK1/2/Col2a1-CreER mice, suggesting reduced vascular invasion (Fig. 6) . This is consistent with the delayed vascularization of the developing secondary ossification center in the long bones. Reduced vascular invasion may at least in part account for the delayed closure of neurocentral synchondroses.
DISCUSSION
Our histological analyses and skeletal measurements of ERK1/2/Col2a1Cre embryos clearly indicated that ERK1/2 is a negative regulator of endochondral bone growth. The inactivation of all four alleles of ERK1 and ERK2 resulted in longer and wider epiphyses of the long bones and larger vertebral bodies. These findings are consistent with our previous observation that increased MEK1 signaling in chondrocytes inhibits endochondral bone growth. 17 While the proximal long bones-the humerus and femur-were significantly longer in ERK1/2/Col2a1Cre embryos, the phenotype was less obvious in the distal bones. Similar overgrowth of the proximal long bones was also described in Fgfr3-deficient mice.
14 Therefore, it is interesting to speculate that chondrocytes in the proximal long bones are more sensitive to Fgfr3 and its downstream ERK1/2 signaling compared with chondrocytes in the distal bones. The observed difference may also be relevant to human achondroplasia, which is characterized by rhizomelic dwarfism, a disproportionate dwarfing of the proximal bones. 6 In contrast to our findings with ERK1/2/ Col2a1Cre embryos, we did not observe obvious differences in the postnatal growth of long bones in ERK1/2/ Col2a1CreER mice. It is possible that our 60% inhibition of ERK2 in addition to ERK1 is not sufficient to promote growth in these mice.
The increased bone growth of ERK1/2/Col2a1Cre embryos may be due to the increase in chondrocyte hypertrophy. We have recently found that ERK1/2/ Col2a1Cre embryos show a remarkable expansion of the zone of hypertrophic chondrocytes in the long bones, while chondrocyte proliferation is strongly inhibited. 26 It has been shown that chondrocyte hypertrophy is a major determinant of longitudinal bone growth. 28, 29 Chondrocyte hypertrophy is also likely to account for the growth in the width in addition to periosteal apposition. Since ERK1/2/Col2a1Cre embryos do not show an obvious periosteal phenotype, periosteal apposition may not be significantly affected in these embryos. The increase in the size of the vertebral body is also associated with the predominant presence of hypertrophic chondrocytes in our current study. Furthermore, these observations are consistent with our previous study showing that increased MEK1 signaling inhibits chondrocyte hypertrophy and bone growth. 17 Since spinal canal stenosis is a common and serious complication of achondroplasia, the effects of ERK1/2 inactivation on spinal canal development are of particular interest. While ERK1/2/Col2a1Cre embryos showed increased dimensions of the vertebral body in both the anterior-posterior and lateral directions, these embryos also showed a narrower spinal canal at E18.5. The increased growth of the cartilaginous vertebral body toward the spinal canal may account for the narrower spinal canal in ERK1/2/Col2a1Cre embryos. In contrast to ERK1/2 inactivation in the prenatal period, the postnatal inactivation of ERK1 and ERK2 resulted in a delay in the closure of the neurocentral synchondroses and an increase in the size of the vertebral foramen, indicating that ERK1/2 regulates the timing of synchondrosis closure and the size of the spinal canal. We have previously found premature synchondrosis closure in mouse models of achondroplasia and in human samples of homozygous achondroplasia and thanatophoric dysplasia. 20 Our observations in ERK1/2/ Col2a1CreER mice indicate that ERK1 and ERK2 would be a promising therapeutic target for spinal canal stenosis caused by activating mutations in FGFR3. Our results in ERK1/2/Col2a1Cre embryos also suggest that ERK1/2 inactivation before the ossification of the vertebral body could result in a narrower spinal canal. The timing of ERK1 and ERK2 inactivation would be critical for the successful enlargement of the spinal canal in the future treatment of achondroplasia.
In summary, we have shown that genetic ERK1 and ERK2 inactivation in chondrocytes enhances the growth of cartilaginous skeletal elements. We have also shown that the postnatal inactivation of ERK1 and ERK2 in chondrocytes delays synchondrosis closure and enlarges the spinal canal. The efficacy of ERK inactivation for the treatment of FGFR3-related skeletal syndromes should be further tested by inactivating ERK1 and ERK2 in mouse models with activating Fgfr3 mutations.
